Page 138 - EJMO-9-3

Eurasian Journal of
Medicine and Oncology KRAS TP53 cholangiocarcinoma

effective and individualized treatment strategies for Oncogenic KRAS addiction states differentially influence
cholangiocarcinoma. MTH1 expression and 8-oxodGTPase activity in lung
adenocarcinoma. Redox Biol. 2025;82:103610.
Acknowledgments doi: 10.1016/j.redox.2025.103610

The authors gratefully acknowledge Zhejiang Chinese 6. Silva JL, De Andrade GC, Petronilho EC, et al. Phase
Medical University for providing expert guidance and separation and prion-like aggregation of p53 family tumor
access to statistical analysis software for this research. suppressors: From protein evolution to cancer treatment.
J Neurochem. 2025;169(4):e70055.
Funding
doi: 10.1111/jnc.70055
None. 7. Zhu XD, Amanjiaoer RH, Shen YL, et al. Combination of
antiangiogenic and systemic therapy in advanced non-
Conflict of interest small cell lung cancer: Before and after progression to
The authors declare no conflicts of interest. leptomeningeal metastasis. Sci Rep. 2025;15(1):11901.
doi: 10.1038/s41598-025-91922-z
Author contributions
8. Kale R, Samant C, Nandakumar K, Ranganath Pai KS,
Conceptualization: Jianan Jin Bhonde M. Drugging the Undruggable and beyond:
Formal analysis: Chuhan Zhang Emerging precision oncology approaches to target acquired
Methodology: Yibin Zhou resistance to KRAS G12C and KRAS G12D inhibitors.
Writing – original draft: Jianan Jin Biochem Biophys Res Commun. 2025;760:151688.
Writing – review & editing: Benfeng Xu doi: 10.1016/j.bbrc.2025.151688
Ethics approval and consent to participate 9. Zheng S, You Z, Guo G, Lin Z, Wang S, Yang G. Effect of
KRAS mutation status on clinicopathological characteristics
Not applicable. and overall survival in patients with rectal cancer. BMC
Gastroenterol. 2025;25(1):37.
Consent for publication
doi: 10.1186/s12876-025-03615-6
Not applicable. 10. Zhao K, Karimi A, Kelly L, et al. TP53 mutation predicts
Availability of data worse survival and earlier local progression in patients
with hepatocellular carcinoma treated with transarterial
Data are available from the corresponding author upon embolization. Current Oncol. 2025;32(1):51.
reasonable request. doi: 10.3390/curroncol32010051

References 11. Moffat GT, Hu ZI, Meric-Bernstam F, et al. KRAS allelic
variants in biliary tract cancers. JAMA Netw Open.
1. Malaguarnera G, Giordano M, Paladina I, et al. Markers of 2024;7(5):e249840.
bile duct tumors. World J Gastrointest Oncol. 2011;3(4):49-59.
doi: 10.1001/jamanetworkopen.2024.9840
doi: 10.4251/wjgo.v3.i4.49
12. Yu H, Xu Y, Gao W, et al. Comprehensive germline and
2. Khan AS, Dageforde LA. Cholangiocarcinoma. Surg Clin somatic genomic profiles of Chinese patients with biliary
North Am. 2019;99(2):315-335. tract cancer. Front Oncol. 2022;12:930611.
doi: 10.1016/j.suc.2018.12.004 doi: 10.3389/fonc.2022.930611
3. Izquierdo-Sanchez L, Lamarca A, La Casta A, et al. 13. Alaimo L, Boggio S, Catalano G, et al. Multi-omics
Cholangiocarcinoma landscape in Europe: Diagnostic, classification of intrahepatic cholangiocarcinoma:
prognostic and therapeutic insights from the ENSCCA A systematic review and meta-analysis. Cancers (Basel).
registry. J Hepatol. 2022;76(5):1109-1121. 2024;16(14):2596.
doi: 10.1016/j.jhep.2021.12.010 doi: 10.3390/cancers16142596
4. Cheng CY, Chen CP, Wu CE. Precision medicine in 14. Ellis H, Braconi C, Valle JW, Bardeesy N. Cholangiocarcinoma
cholangiocarcinoma: Past, present, and future. Life (Basel). targeted therapies: Mechanisms of action and resistance. Am
2022;12(6):829. J Pathol. 2025;195(3):437-452.
doi: 10.3390/life12060829 doi: 10.1016/j.ajpath.2024.11.005
5. Mateo-Victoriano B, Samaranayake GJ, Pokharel S, et al. 15. Stang A. Critical evaluation of the Newcastle-Ottawa scale

Volume 9 Issue 3 (2025) 130 doi: 10.36922/EJMO025120063